Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE) insider Sheldon Sloan sold 78,333 shares of Spyre Therapeutics stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $71.50, for a total value of $5,600,809.50. Following the completion of the transaction, the insider directly owned 78,333 shares in the company, valued at approximately $5,600,809.50. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sheldon Sloan also recently made the following trade(s):

• On Wednesday, April 1st, Sheldon Sloan sold 7,958 shares of Spyre Therapeutics stock. The stock was sold at an average price of $50.00, for a total value of $397,900.00.

Spyre Therapeutics Price Performance

Spyre Therapeutics stock opened at $69.42 on Monday. The stock’s 50 day moving average is $51.75 and its 200 day moving average is $37.61. The firm has a market cap of $5.47 billion, a P/E ratio of -33.38 and a beta of 3.12. Spyre Therapeutics, Inc. has a one year low of $12.28 and a one year high of $76.00.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). Equities analysts anticipate that Spyre Therapeutics, Inc. will post -2.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Stifel Nicolaus lifted their target price on Spyre Therapeutics from $70.00 to $92.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Leerink Partners lifted their target price on Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a report on Monday, April 13th. Wedbush lifted their target price on Spyre Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, April 13th. Deutsche Bank Aktiengesellschaft lifted their target price on Spyre Therapeutics from $55.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Finally, JonesTrading lifted their target price on Spyre Therapeutics from $64.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $85.08.

Key Headlines Impacting Spyre Therapeutics

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
• Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
• Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (≈$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
• Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
• Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows

Institutional Investors Weigh In On Spyre Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Candriam S.C.A. increased its holdings in shares of Spyre Therapeutics by 43.4% during the first quarter. Candriam S.C.A. now owns 610,282 shares of the company’s stock valued at $30,783,000 after acquiring an additional 184,748 shares in the last quarter. Summit Securities Group LLC bought a new stake in shares of Spyre Therapeutics during the first quarter valued at approximately $28,000. Strs Ohio bought a new stake in shares of Spyre Therapeutics during the first quarter valued at approximately $227,000. Union Bancaire Privee UBP SA bought a new stake in shares of Spyre Therapeutics during the first quarter valued at approximately $196,000. Finally, High Net Worth Advisory Group LLC bought a new stake in shares of Spyre Therapeutics during the first quarter valued at approximately $303,000. Institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.